相关实验视频

Updated: Mar 12, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

嵌合式抗原受体T细胞治疗在消化系统恶性瘤中的进展和挑战

Chen Wang¹, Jin Zhang², Zi-Ke Chen¹

¹Department of Gastroenterology, Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.

World journal of clinical oncology

|March 11, 2026

概括

化学抗原受体T细胞 (CAR-T) 疗法对消化系统癌症显示出前景. 研究正在推动CAR-T的发展,针对特定的抗原来克服治疗这些固体瘤的挑战.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胃肠道瘤学胃肠道瘤学

背景情况:

化学抗原受体T细胞 (CAR-T) 疗法已经改变了血液恶性瘤治疗.
固体瘤,特别是消化系统癌症,在CAR-T治疗方面取得了有限的成功.
消化系统恶性瘤对全球健康构成重大挑战.

研究的目的:

审查最近对消化系统瘤的CAR-T疗法的进展.
概述瘤特异性标和正在进行的临床试验.
讨论CAR-T在固体瘤中的挑战,解决方案和未来方向.

主要方法:

对主要消化系统瘤的CAR-T开发近期进展的审查.
确定瘤特异性点和相关的临床试验.
对CAR-T疗法的当前挑战和潜在策略的分析.

主要成果:

在抗原选择,CAR设计和消化系统癌症的输送方法方面取得了重大进展.
确定各种消化系统恶性瘤的关键点并启动临床试验.
新兴的解决方案,以克服对固体瘤CAR-T疗效的挑战.

结论:

卡尔-T疗法具有治疗消化系统癌症的潜力.
持续的研究和战略开发对于在固体瘤中推进CAR-T至关重要.
下一代CAR-T疗法正在开发中,以改善这些具有挑战性的恶性瘤的治疗结果.

关键词:

化学抗原受体T细胞治疗化学抗原受体的设计消化系统瘤消化系统瘤胃肠道的癌症胃肠道的癌症免疫治疗是一种免疫疗法.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.